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ABSTRACT
Purpose: Progression of stable coronary artery
disease (CAD) towards acute coronary syndrome (ACS)
is a dynamic and heterogeneous process with many
intertwined constituents, in which a plaque
destabilising sequence could lead to ACS within short
time frames. Current CAD risk assessment models,
however, are not designed to identify increased
vulnerability for the occurrence of coronary events
within a precise, short time frame at the individual
patient level. The BIOMarker study to identify the Acute
risk of a Coronary Syndrome (BIOMArCS) was
designed to evaluate whether repeated measurements
of multiple biomarkers can predict such ‘vulnerable
periods’.
Participants: BIOMArCS is a multicentre, prospective,
observational study of 844 patients presenting with
ACS, either with or without ST-elevation and at least
one additional cardiovascular risk factor.
Methods and analysis: We hypothesised that
patterns of circulating biomarkers that reflect the
various pathophysiological components of CAD, such
as distorted lipid metabolism, vascular inflammation,
endothelial dysfunction, increased thrombogenicity and
ischaemia, diverge in the days to weeks before a
coronary event. Divergent biomarker patterns, identified
by serial biomarker measurements during 1-year
follow-up might then indicate ‘vulnerable periods’
during which patients with CAD are at high short-term
risk of developing an ACS. Venepuncture was
performed every fortnight during the first half-year and
monthly thereafter. As prespecified, patient enrolment
was terminated after the primary end point of
cardiovascular death or hospital admission for non-
fatal ACS had occurred in 50 patients. A case–cohort
design will explore differences in temporal patterns of
circulating biomarkers prior to the repeat ACS.
Future plans and dissemination: Follow-up and
event adjudication have been completed. Prespecified
biomarker analyses are currently being performed and
dissemination through peer-reviewed publications and
conference presentations is expected from the third
quarter of 2016. Should identification of a ‘vulnerable
period’ prove to be feasible, then future research could
focus on event reduction through pharmacological or
mechanical intervention during such periods of high
risk for ACS.
Trial registration number: NTR1698 and NTR1106.
INTRODUCTION
Generalised cardiovascular (CV) risk assess-
ment models have proven to be valuable for
Strengths and limitations of this study
▪ The only currently available study cohort of
patients with coronary artery disease with such
high frequency blood sampling in order to inves-
tigate multiple biomarker patterns shortly prior
to a coronary ischaemic event.
▪ Prospective sample collection with ‘retrospective’
biomarker and genetic analyses after event
adjudication.
▪ Strict and prespecified study/laboratory processing
protocol minimising preanalytical confounding.
▪ The BIOMarker study to identify the Acute risk of
a Coronary Syndrome (BIOMArCS) does not aim
to unravel whether certain biomarkers are merely
markers reflecting pathways of disease, or med-
iators that are directly involved within distinct
pathophysiological cascades in the arterial wall.
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longer term risk prediction in primary prevention settings,
such as Framingham and SCORE,1 2 as well as in patients
who experienced an acute coronary syndrome (ACS),
such as the PURSUIT, TIMI and GRACE risk models.3–5
Existing CV risk models largely depend on the presence
and recognition of traditional risk factors and CV history
complemented by biometric factors. Traditional CV risk
factors, however, are absent in a signiﬁcant part of the
population that nevertheless develops coronary artery
disease (CAD).6 In contrast, the prevalence of traditional
risk factors is also high among those fractions of the popu-
lation that will never endure a CV event.7
According to the key philosophy behind existing CV
risk prediction models, the individual patient is consid-
ered to be a member of a group that is exposed to a
certain (low-intermediate-high) constant risk, whereas the
incidence of acute CV events is considered a random
process, with event probabilities directly related to that
group risk. Consequently, CV risk models usually predict
reasonably well on a group level, but only poorly outline
the course of individuals.8 In addition, current risk predic-
tion models do not account for the dynamic nature of the
atherosclerotic vascular wall of individual patients.
Individual patients with CAD actually do not have con-
stant risks over time.9 Long periods of stability, with
minimal plaque progression and low risk of CV events,
are alternated by periods of increased plaque instability
and rapid plaque progression,10 during which the risk of
sudden plaque disruption and thrombotic coronary
occlusion within short time spans is high.11 12 This is a
complex and multifactorial pathophysiological process in
which temporal variations in distorted lipid metabolism,
vascular inﬂammation, endothelial dysfunction, increased
thrombogenicity and myocardial ischaemia play an
important role.9 11 Various established and novel serum
biomarkers have been associated with each of these
pathophysiological components, reﬂecting their presence
and/or activity.11 13–20 Furthermore, the biomarker’s
ability to ﬂuctuate, at least in theory, perfectly suits moni-
toring short-term risks of a dynamic pathophysiological
process, as CAD. Integration of such dynamic information
requires a conceptionally different perspective on risk
prediction. Ideally, such a different approach might result
in more precise and time-speciﬁc risk assessment for the
occurrence of adverse cardiac events.
Therefore, we hypothesised that divergent biomarker
patterns, detected through ambulatory and highly fre-
quent blood sampling, could identify patients in a ‘vul-
nerable period’ for the occurrence of an imminent
myocardial infarction (MI). In order to investigate this
hypothesis, our aim was to obtain serial biomarker mea-
surements as closely as possible prior to an ischaemic
event, yet in a phase in which the patient is still asymp-
tomatic. Subsequent analysis of serial biomarker patterns
up to the coronary event should elucidate biomarker
kinetics, patterns, appropriate cut-off values and predic-
tion characteristics (such as time frames), particularly
shortly prior to the actual occurrence of an ACS.
COHORT DESCRIPTION
Study objectives
We designed the BIOMarker study to identify the Acute risk
of a Coronary Syndrome (BIOMArCS) to evaluate whether
biomarker patterns of (vascular) inﬂammation, distorted
lipid metabolism, endothelial dysfunction, decreased
endothelial regenerative capacity, increased thrombo-
genicity and ischaemia diverge in days to weeks prior to
an ACS. If our hypothesis is conﬁrmed, then serial bio-
marker measurements might identify ‘vulnerable
periods’ in the lifetime of patients with prevalent CAD,
during which they are at increased risk of developing an
ACS. Various hypothetically divergent biomarker pat-
terns are depicted in ﬁgure 1 (panel A: divergence
shortly prior to an ACS, panel B: persistently higher (or
lower) biomarker levels in the future cases, panel C:
higher intraindividual variability in the future cases).
Study cohort
BIOMArCS is a multicentre, prospective, observational
study conducted in 18 participating hospitals in the
Netherlands. Patients who were admitted for an ACS,
including unstable angina pectoris, non-ST-elevation MI
and ST-elevation MI (STEMI) with at least one add-
itional CV risk factor, were eligible for enrolment (table
1). A total of 844 patients were enrolled from 1 March
2008 until 26 January 2015. Table 2 describes the base-
line clinical characteristics of the enrolled cohort.
Blood samples were collected at admission, at the day of
hospital discharge and subsequently every fortnight during
the ﬁrst 6 months after discharge, followed by monthly
blood sample collection until 1 year. Patients were offered
some ﬂexibility in the follow-up scheme: visit windows are
±1 week, and a maximum of two consecutive visits are
allowed to be skipped (for personal reasons). If logistic cir-
cumstances hindered inclusion during hospitalisation,
patients could be included on the ﬁrst outpatient visit
within 6 weeks after discharge. The sample collection
schedule was then adapted accordingly. Follow-up blood
sampling was terminated permanently after coronary artery
bypass grafting (CABG), hospital admission for heart
failure or a deterioration of renal function leading to a
glomerular ﬁltration rate <30 mL/min/1.73 m2, in order
to minimise bias in circulating biomarker concentrations.
During the course of the study, we observed prespeciﬁed
discontinuation of biomarker sampling in 13 patients who
were revascularised through CABG at a median follow-up
duration of 116 days after the index ACS. In these patients,
samples were taken up until the bypass operation.
A trained research nurse interviewed the patients at
each visit and obtained data on anginal status (Canadian
Cardiovascular Society classiﬁcation), heart failure symp-
tomatology (New York Heart Association classiﬁcation)
and speciﬁc factors that might inﬂuence biomarker
levels, for example, smoking, the occurrence of infec-
tions, inﬂammatory or allergic responses, alterations in
medication, interventional or operative procedures and
hospital admission.
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This is an observational study. As such, it does not
interfere with patient treatment. All patients were
treated as per prevailing guidelines and at the discretion
of the investigator. Patients were only included after they
provided written informed consent. The consent
enables the investigators to enquire on the patients’
health status up to 15 years after enrolment.
Blood sample collection
Blood samples were ﬁrst handled and securely stored
on-site. After preparation, aliquots were frozen at −80°C
within 2 hours after withdrawal. Long-term storage and
biomarker analysis will take place at the department of
Clinical Chemistry of the Erasmus MC. Apart from
storage of serum, citrate-plasma and EDTA-plasma, the
BIOMArCS laboratory protocol also foresaw in collection
and preservation of leucocytes for the purpose of
genome analyses and ﬂow cytometric measurements of
certain circulating leucocyte (monocyte) subsets that are
thought to reﬂect endothelial regenerative capacity.21
Study end points
The primary end point is a composite of cardiac mortal-
ity or a clinical diagnosis of a non-fatal MI or unplanned
coronary revascularisation due to progressive angina
pectoris during 1-year follow-up. Any death will be con-
sidered cardiac unless documented to the contrary.
Incident non-fatal MI is deﬁned as the combination of
typical ischaemic chest symptoms and objective evidence
of myocardial ischaemia or myocardial necrosis as
demonstrated by ECG and/or elevated cardiac markers.
The criteria for non-fatal MI during follow-up share the
same deﬁnition as stated for the index event (points 1
and 2 of the study inclusion criteria). Study end points
at 1-year follow-up were adjudicated by a Clinical Event
Committee whose members were blinded for all bio-
marker data collected prior to the suspected incident
event. At a later stage, events that occur after the ﬁrst
year and up to 15 years of follow-up (ie, in the period
without repeated blood sampling) will be adjudicated
accordingly.
Sample size considerations
The incidence of the primary end point was estimated at
5–7%. Consequently, the number of patients who experi-
ence the primary end point (cases) will be far less than
those who remain end point-free. For reasons of efﬁ-
ciency, we will therefore apply the case–cohort design,22
and temporal biomarker patterns of all cases will be
compared with a limited number of non-cases.
For an adequate estimate of the required sample size,
we applied 500 simulations of linear mixed-effects
models for several scenarios (table 3), which were based
on repeated low-density lipoprotein-cholesterol (LDL-C)
measurements from a pilot study with up to ﬁve mea-
surements in 30 non-cases (non-published data). LDL-C
was considered the dependent variable and end point
status the explanatory variable. We assumed that, on
average, 6–10 repeated blood samples will be available in
cases prior to the primary end point. Then, if 50 cases
will be compared with 2–3 non-cases, a difference in the
intercept of 0.17–0.21 mmol/L, and a difference in the
Figure 1 Different hypothetical scenarios of biomarker
evolution during stable and vulnerable periods in the lifetime
of a patient with coronary artery disease. Panel A describes a
scenario in which biomarker patterns are relatively stable in a
period of low coronary vulnerability, but are clearly divergent
and upregulated shortly prior to the primary end point. Panel
B describes a potential scenario in which the ‘vulnerable
period’ for a coronary event is relatively longer and
characterised by persistently higher biomarker levels.
Depending on the specific biomarker, this scenario could also
apply in case of persistently lower (instead of higher) levels.
Panel C depicts a divergent biomarker pattern in which a high
degree of variability is associated with an increased risk of
adverse cardiac outcome. Naturally, numerous variations and
combinations of the aforementioned scenarios can be
proposed for each specific biomarker depending on its
characteristic pattern and kinetics.
Oemrawsingh RM, et al. BMJ Open 2016;6:e012929. doi:10.1136/bmjopen-2016-012929 3
Open Access
slope of 0.06–0.11 mmol/L/month can be demonstrated
between cases and non-cases with a power of 80% (two-
sided test with an α error of 5%). We judged that these
differences are small in clinical terms, and we consid-
ered the observed variations in LDL-C levels represen-
tative of changes in other biomarkers. In order to
obtain 50 cases, given the anticipated incidence, a total
of 700–1000 patients needed to be enrolled.
Construct of the case–cohort analysis set
A random, representative sample of 150 patients
(random subcohort) will be chosen from all enrolled
patients, and the patients who reach a study end point
will be added. We anticipate that (50/1000)×150=8 to
(50/700)×150=11 patients of the random subcohort will
reach the primary end point. Hence, the expected ratio
between patients with and without the primary study
end point in the analysis set will be 1:2.8–1:2.9, which
allows us to reveal clinically relevant differences in bio-
marker patterns with sufﬁcient statistical power (see
Sample size considerations section above).
Biomarker selection and significance testing
Atherosclerosis and plaque destabilisation leading to
intracoronary thrombosis and an ACS is the result of a
very heterogeneous process with many intertwined
Table 1 Inclusion and exclusion criteria
Inclusion: a patient must meet all criteria
1 Age ≥40 years
2 Symptoms of typical ischaemic chest pain, lasting
10 min or more within the preceding 24 hours prior to
presentation
3a ECG: (non-)persistent ST segment elevation >1.0 mm
in two or more contiguous leads, or dynamic ST
segment depression >1.0 mm in two or more
contiguous leads, OR
3b Biochemical evidence of myocardial injury: CKMB or
(high-sensitivity) troponin I or (high-sensitivity)
troponin T elevation according to the applicable ESC
guidelines of non ST-elevation acute coronary
syndromes
4 Presence of at least one of the following risk factors: age
≥75 years, diabetes, prior cardiovascular disease, prior
cerebrovascular disease and prior peripheral arterial
disease. In addition, other risk factors mentioned below
can be considered as well, but each only counts as half
a risk factor, that is, two of these are required for
inclusion: age ≥65 years in men, age ≥70 years in
women, hypertension, hypercholesterolaemia, current
smoking or microalbuminuria,* positive family history of
coronary artery disease.†
5 Written informed consent
Exclusion: a patient cannot be included in case of any
of the criteria below
1 Myocardial ischaemia precipitated by a condition
other than atherosclerotic coronary artery disease
2 Left ventricular ejection fraction <30%, or end-stage
congestive heart failure (NYHA class III or IV)
3 Renal dialysis, or severe chronic kidney disease with
measured or calculated GFR (Cockroft-Gault or
MDRD4 formula) of <30 mL/min/1.73 m2
4 Coexistent condition with life expectancy <1 year or
otherwise not expected to complete follow-up
*Defined as >2.5 to 25 mg albumin/mmol creatinine for men and
>3.5 to 35 mg for women, or >20 to 200 mg/L urinary albumin
concentration in a single urine sample.
†Angina pectoris, myocardial infarction or sudden abrupt death
without obvious cause, before the age of 55 in a first-degree blood
relative.
GFR, glomerular filtration rate; MDRD, Modification of Diet in
Renal Disease; NYHA, New York Heart Association classification.
Table 2 Baseline characteristics of the entire cohort of
844 patients
Presentation and initial treatment
Age, years 62.5 (54.3, 70.2)
Man 77.9
Admission diagnosis
STEMI 51.7
NSTEMI 37.7
UAP 10.6
Culprit artery
RCA 33.1
LM 2.5
LAD 31.9
LCX 16.5
Coronary angiography performed 94.4
Percutaneous coronary intervention 86.3
Maximum CK during admission (iU/L) 513 (200, 1370)
Cardiovascular risk factors
Current smoking 40.5
Diabetes mellitus 23.5
Hypertension 55.5
Hypercholesterolaemia 49.3
Cardiovascular history
Prior percutaneous coronary
intervention
26.2
Prior coronary artery bypass grafting 10.0
Prior myocardial infarction 26.9
Prior heart failure 2.4
Valvular heart disease 2.2
Prior stroke 9.0
Peripheral artery disease 8.9
Medication at first blood sample moment
Aspirin 95.3
P2Y12 inhibitor 95.2
Vitamin K antagonist 6.8
Statin 96.2
β-blocker 89.8
ACE inhibitor or ARB 82.9
Continuous data are presented as median (25th, 75th percentiles)
values. Categorical data are presented as percentages. There are
no missing data for any of the aforementioned variables.
ARB, angiotensin II receptor blocker; CK, creatine kinase; LAD,
left anterior descending artery; LCX, left circumflex artery; LM, left
main coronary artery; MI, myocardial infarction; NSTEMI,
non-ST-elevation myocardial infarction; RCA, right coronary artery;
STEMI, ST-elevation myocardial infarction; UAP, unstable angina
pectoris.
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constituents. Vascular inﬂammation and endothelial dis-
ruption can result in thrombosis, which in turn can
exacerbate inﬂammation.11 Many of the circulating bio-
markers that have been shown to adequately predict
risks of future CV events are therefore thought to reﬂect
one or more of these distinct yet interdependent patho-
physiological processes more or less speciﬁcally.
Currently, markers like those mentioned in box 1 are
considered to have high potential, and will be deter-
mined and reported in prespeciﬁed consecutive phases.
Their selection is hypothesis-driven and based on
current literature, which is mainly based on one single
measurement in time.13–19 23–30 The development of
biomarker levels shortly after presentation for ACS, and,
more importantly, the frequently sampled biomarker
patterns during the (asymptomatic) period preceding a
subsequent event are unknown. A call for epidemio-
logical research to establish the clinical value of serial
analysis of biomarkers in atherosclerotic disease during
long-term follow-up has repeatedly sounded,12 31 32 but
has not been answered as yet.
We will not limit our analyses to a selected number of
markers. Biomarker research is a very rapidly evolving
ﬁeld in which novel and promising markers are regularly
discovered. Exploratory analyses using proton nuclear
magnetic resonance spectroscopy and mass spectrometry
are also an option under consideration.30
We will perform several statistical tests to obtain signiﬁ-
cance levels for relations between biomarkers and study
end points. For hypothesis-driven tests, a two-tailed sig-
niﬁcance level of 0.05 will be used. For hypothesis-free
tests, corrections for inﬂation of the type I error due to
multiple testing will be applied.
Aetiological and prognostic analyses of selected
biomarkers
Compared with an analysis of the entire cohort, the advan-
tage of a case–cohort design lies in its efﬁciency, whereas
the ability to calculate absolute risks and rates is main-
tained.22 We will perform aetiological as well as prognostic
analyses. We will use the framework of linear mixed-effects
models to assess changes in biomarker levels over time,
while accounting for the correlation between repeated
follow-up measurements in each patient.33 For both the
ﬁxed-effects and random-effects parts of the model, we will
test for possible non-linear evolutions, which will be mod-
elled by restricted cubic splines.
Biomarkers represent endogenous time-dependent
covariate processes. We will therefore use the framework
of joint models for longitudinal and survival data to
investigate the relation between the serial biomarker
measurements and the study end points.34 Joint models
combine the aforementioned linear mixed-effects
models with a Cox regression model, adapted for a
case–cohort design,35 in order to measure the strength
of the association between the two outcomes. We will
test whether the (instantaneous) slope of the biomarker
trajectory is associated with the study end point.
Both univariate and multivariate analyses will be applied.
The biomarker trajectories in the linear models will be
adjusted (1) for age and sex, (2) GRACE risk score, (3)
kidney function, (4) body mass index, diabetes mellitus,
prior CAD, prior cerebrovascular disease and prior periph-
eral vascular disease, and (5) other variables that appear
related to biomarker levels in the analysis set, to the extent
that is permitted given the number of observations. The
relation between biomarkers and study end points in the
Cox model will be adjusted for GRACE risk score and prog-
nostic biomarkers to the extent that is permitted, given the
number of end point cases. For the purpose of multivariate
adjustment, we will select the speciﬁc GRACE risk model
that is best in line with the purpose of our study, namely an
assessment of postdischarge death and MI. That particular
GRACE risk model consists of age, troponin (or CKMB)
elevation at admission, history of MI, congestive heart
failure and whether CABG was performed at the index
hospitalisation.36
Risk models
Based on the results of the analyses above, multibiomar-
ker models will be constructed to predict the risk of the
study end points based on the temporal evolvement of
Table 3 Results of simulations (500 for each scenario) to obtain an adequate estimate of the required sample size
Number of cases
Number of
non-cases
Number of repeated
samples pp
Difference in
intercept (mmol/L)
Difference in slope
(mmol/L/month)
45 90 6 0.22 0.11
45 90 10 0.19 0.06
45 135 6 0.20 0.10
45 135 10 0.17 0.06
50 100 6 0.21 0.11
50 100 10 0.18 0.06
50 150 6 0.19 0.10
50 150 10 0.17 0.06
70 140 6 0.17 0.09
70 140 10 0.15 0.05
70 210 6 0.16 0.08
70 210 10 0.14 0.05
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the biomarkers. We realise that the number of biomar-
kers (and covariates) will be limited by the number of
end point events.37
Early washout biomarker patterns and ancillary analyses
In an ancillary study of 68 patients (10% of the initially
planned total study population of at least 700 patients),
we aim to study the evolution/normalisation of biomar-
kers during the ﬁrst 8 weeks after the index event. In
these patients, (additional) blood samples are collected
within 24, 48, 72 and 96 hours after admission, at the
day of hospital discharge, and at 2, 4 and 8 weeks after
discharge. Insight into these patterns will allow us to
differentiate whether observed divergent biomarker
patterns prior to a repeat ACS during longer term
follow-up are (partly) inﬂuenced by biochemical conse-
quences of the index event.
Patients will use multiple medications that might inﬂu-
ence biomarker levels (eg, β-blockers, ACE-inhibitors
and especially statins are known for their pleiotropic
effects). However, for ethical reasons, we will not inter-
fere with the patient’s treatment. Biomarkers might also
be inﬂuenced by inﬂammatory processes due to other
illnesses. We will analyse these phenomena descriptively.
Study organisation
The study is conducted under the leadership of an
executive committee that has overall responsibility for
protocol design, study conduct and publication. The
Clinical Epidemiology Unit of the Erasmus MC
Department of Cardiology serves as the coordinating
centre for the study and oversees all activities including
(outpatient) clinical follow-up, data management and
statistics, as well as blood sample handling, transport
and long-term storage.
Current status
BIOMArCS enrolled 844 patients between 1 March 2008
and 26 January 2015 (table 2). Currently, 1-year
follow-up and event adjudication have been completed.
Prespeciﬁed biomarker analyses are currently being per-
formed and dissemination through peer-reviewed publi-
cations and conference presentations is expected from
the third quarter of 2016.
DISCUSSION
Vulnerable period versus vulnerable plaque
The notion of the ‘vulnerable plaque’ has gained cur-
rency in recent years, partly because the concept of an
inﬂamed, rupture-prone, thin-capped ﬁbroatheroma ﬁts
well within our current understanding of atherosclerosis
biology. Still, it remains important to realise that ex vivo
as well as in vivo studies using coronary intravascular
ultrasound in patients with MI have demonstrated the
presence of vulnerable plaques in other than the culprit
lesion or even culprit artery.38 39 In other words, vulner-
able plaques are numerous and a certain part of the
plaques that we may classify as vulnerable will never
disrupt.11 Understanding of the clinical implications of
the presence of vulnerable plaques becomes even more
difﬁcult given the observations that, even in the case of
plaque disruption and thrombus formation, this does
not always imply a major symptomatic event, since many
coronary thrombi remain mural and produce few if any
symptoms.40
By selection of a clinically relevant end point and by
analysis of biomarkers at various time points prior to the
end point, BIOMArCS is well suited to identify a ‘vulner-
able period’ during the follow-up of a ‘vulnerable
patient’, instead of merely detecting the presence and a
certain degree of destabilisation of vulnerable plaques.
Box 1 Biomarker selection
The following biomarkers are considered of high potential with
regard to the BIOMarker study to identify the Acute risk of a
Coronary Syndrome (BIOMArCS) hypothesis and will be deter-
mined and reported in prespecified consecutive phases. Their
selection is hypothesis-driven and based on current literature.
Phase 1
High sensitivity C reactive protein1
High sensitivity troponin I1
High sensitivity troponin T2
NT-pro BNP3
ST-24
Creatinine1
Total cholesterol, high-density lipoprotein cholesterol1,
low-density lipoprotein cholesterol5
Phase 2 (in alphabetical order)
Copeptin
Ceramide (d18:1/16:0) as well as the following ceramide ratios:
Cer(d18:1/16:0)/Cer(d18:1/24:0)
Cer(d18:1/20:0)/Cer(d18:1/24:0)
Cer(d18:1/24:1)/Cer(d18:1/24:0)
Cystatin-C
Galectin-3
Growth differentiation factor-15
Interleukins 1, 6, 8, 10, 18
Monokine-induced by interferon-γ
Myeloperoxidase
Placental growth factor
Plasminogen activator inhibitor 1
Pregnancy-associated plasma protein A
Regulated on activation normal T cell expressed and secreted
Soluble CD40 ligand
Tumour necrosis factor
Von Willebrand factor
Analyses of the markers in the first phase are to be performed on the
following platforms/assays:
1. Coulter 5800 series, Beckman Coulter, Brea, California, USA
2. Cobas, Roche Diagnostics GmbH, Mannheim, Germany
3. Custom-built ELISA
4. Presage ST2 assay, Critical diagnostics, San Diego, California, USA
5. Friedewald Formula
Assays for the markers in the second phase have currently not been
selected yet.
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Rationale behind the time intervals for sample collection
The average time from collection of the last blood
sample in asymptomatic condition until the occurrence
of the coronary event will be 7 days in case of an event
during the ﬁrst 6 months after enrolment and 14 days
during the latter half-year of follow-up. Since similar
studies have not been conducted before, there is a
concern that altered biomarker patterns indicating an
imminent event might be missed due to the length of
the intervals between individual samples. However, more
frequent blood sampling than proposed in the current
protocol would test the boundaries of an ethically
acceptable burden for study patients. Furthermore, it is
important to realise that the longer term aim is to strive
for implementation of serial multimarker testing in the
routine follow-up of ambulatory patients. Recognition of
distinct short-term future periods of high coronary vul-
nerability could in the near future serve to prevent the
imminent event by intensiﬁcation of treatment (by
pharmacological and/or percutaneous coronary inter-
vention) in individuals who are selected on the basis of
a divergent ‘biomarker signature’. Future long-term
routine clinical follow-up of patients in an even more
frequent scheme of sampling seems practically unfeas-
ible and reliable point-of-care multimarker tests that are
not semiquantitative currently do not exist. Moreover,
interventions to prevent the so-called imminent event
require time as well.
Although the BIOMArCS concept is very novel, there
is some, though limited, evidence that the chosen time
intervals of our exploratory and clinically adaptable
protocol in fact do allow observation of upregulation of
pathophysiological mechanisms leading to an ACS.
Rittersma et al41 used a pathological classiﬁcation of
aspired intracoronary thrombi to demonstrate that, in at
least 50% of patients with STEMI, coronary thrombi
were days or even weeks old. This supports our hypoth-
esis that sudden coronary occlusion is often preceded by
a variable period of coronary instability and thrombus
formation, initiated days or weeks before onset of symp-
toms. A second study evaluated formalin stored hearts
and tissue blocks of coronary arteries including the
thrombosed culprit plaque of young adults (≤35 years)
who had died within 1 hour after onset of symptoms due
to a coronary thrombotic occlusion and drew a similar
conclusion.42 A third study used platelet mRNA proﬁling
in order to demonstrate that the expression of a certain
biomarker, myeloid-related protein-14, is upregulated
prior to STEMI. Since platelets are anuclear, the platelet
transcriptome mirrors megakaryocyte-derived mRNAs
and represents an averaged mRNA proﬁle of variably
aged platelets (platelets circulate for 7–10 days).43
Finally, serial angiographic studies in the 1990s have
demonstrated a sudden rapid lesion progression in
weeks to months prior to MI.10 44 45 The possible
mechanisms for such rapid plaque progression and con-
sequent luminal obstruction include recurrent plaque
rupture and healing, intraplaque neovascularisation and
haemorrhage with deposition of erythrocyte-derived free
cholesterol.10
Future directions
As indicated previously, the longer term perspective of this
study is to recognise distinct periods of high coronary vul-
nerability in individual patients days to weeks in advance,
so that a tailored therapy and intensiﬁcation of treatment
might prevent the imminent event. Biomarker patterns
and kinetics following and prior to an ACS have not been
described before at such short intervals during 1-year
follow-up. This study will therefore provide insight into the
usefulness of combinations of certain markers for risk pre-
diction at such short term. The descriptive data collected
in this study could be used for the construction of a short-
term and longer term multimarker risk prediction model.
Current risk prediction models are generally characterised
by their use of baseline patient characteristics and lack of
account of disease characteristics and progression over
time. A multimarker approach, in which a combination of
different biomarkers actually reﬂects atherosclerosis
biology and dynamics, might therefore improve overall
risk prediction. Of course, such an assertion also implies
epidemiological challenges. Prediction on the basis of
short-term repeated measurements that reﬂect risks that
are dynamic over time, instead of linear and continuous,
requires alternative statistical approaches.
At a later stage (and dependent on the results of the
aforementioned projects), the way could be paved towards
intervention studies that evaluate the effectiveness and
safety of a brief period of intensiﬁed medical treatment
(or a percutaneous intervention) in order to prevent an
otherwise imminent coronary event, as characterised by an
abnormal ‘high-risk’ biomarker pattern. Future hypoth-
eses could focus on plaque stabilisation or regression and
endothelial repair in patients with ‘high-risk’ biomarker
patterns such as a brief period of intravenous administra-
tion of apolipoprotein-A1 Milano,46 proprotein convertase
subtilisin/kexin type 9 inhibition,47 or the use of the anti-
inﬂammatory properties of P-selectin antagonists,48
low-dose colchicine49, low-dose methotrexate or
interleukin-1β inhibition.50 Perhaps divergent biomarker
patterns could be evaluated for selection of patients who
beneﬁt from prolonged dual antiplatelet therapy.
Exogenous drugs such as agonists of vascular endothelial
growth factor, peroxisomal proliferative-activated receptor
agonists and granulocyte colony-stimulating factor, which
exert their actions partly through endothelial progenitor
cell-mediated re-endothelialisation may be of interest as
well.51
Obviously, the data generated by this study could also be
used for the identiﬁcation of individuals with a ‘low-risk’
biomarker pattern. Tailored therapy for them might imply
a reduction in pharmacological treatment regimes.
Strengths and limitations
BIOMArCS is the only currently available study in which
such frequent blood sampling has been performed on a
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large scale in order to thoroughly investigate multiple
biomarker patterns in patients with CAD. As such,
BIOMArCS is conceptionally different from all other
biomarker studies in patients with CAD, as it aimed to
obtain blood samples as shortly as possible prior to a
future adverse cardiac event. Although sample collection
was performed prospectively, biomarker and genetic ana-
lyses will be performed retrospectively. As a dedicated
biomarker study it beneﬁts from a strict and prespeciﬁed
laboratory processing protocol in which preanalytical
confounding was minimised through standardisation of
methods and materials for blood collection in all
centres. Time from collection to standardised processing
and freeze and thaw cycles for biomarker analyses are
limited by protocol. Patients were interviewed at each
venepuncture to inquire about their cardiac status and
medication use, as well as about confounders of speciﬁc
biomarkers (eg, new onset of other illnesses, infection,
allergic reactions.)
It is important to emphasise that a clinical observa-
tional study such as BIOMArCS does not aim to unravel
whether certain biomarkers are merely markers reﬂect-
ing pathways of disease, or mediators that are directly
involved within distinct pathophysiological cascades in
the arterial wall. Deﬁnite delineation of biochemical
events responsible for observed alterations in biomarker
patterns prior to the end point, or ﬁnal conclusions on
mechanisms of disease are beyond the scope of this study
design. In addition, our study was performed in patients
with a known CAD. It is uncertain whether its conclusions
may be extrapolated to the primary prevention setting.
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